Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Alkaloids
  • Antineoplastic Agents
  • Breast Neoplasms
  • Ellipticines
  • Kidney Neoplasms

abstract

  • Elliptinium, 100 mg/m2 i.v. weekly, was administered to 14 patients with advanced renal cancer and 4 with breast cancer. There were no responses in 11 adequately treated patients. An unexpectedly high incidence of xerostomia, allergic, and hemolytic reactions were observed, which resulted in cessation of the trial. Recent data suggest polymer formation occurs with reconstituted elliptinium, and further trials are warranted when a new formulation is available.

publication date

  • November 28, 1985

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 4037737

Additional Document Info

start page

  • 415

end page

  • 7

volume

  • 5

number

  • 4